日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

The novel DNA cross-linking agent KL-50 is active against patient-derived models of new and recurrent post-temozolomide mismatch repair-deficient glioblastoma.

新型 DNA 交联剂 KL-50 对替莫唑胺治疗后新发和复发性错配修复缺陷型胶质母细胞瘤的患者来源模型具有活性

期刊:Neuro-Oncology
影响因子:13.4
doi:10.1093/neuonc/noae257
McCord Matthew, Sears Thomas, Wang Wenxia, Chaliparambil Rahul, An Shejuan, Sarkaria Jann, James C David, Ruggeri Bruce, Gueble Susan, Bindra Ranjit, Horbinski Craig
细胞生物学
发表日期：2025
文献求助 收藏

The Bromodomain Inhibitor, INCB057643, Targets Both Cancer Cells and the Tumor Microenvironment in Two Preclinical Models of Pancreatic Cancer

溴结构域抑制剂INCB057643在两种胰腺癌临床前模型中均能靶向癌细胞和肿瘤微环境。

期刊:Cancers
影响因子:4.4
doi:10.3390/cancers13010096
Leal, Ana S; Liu, Phillip; Krieger-Burke, Teresa; Ruggeri, Bruce; Liby, Karen T
肿瘤
肿瘤免疫
细胞生物学
胰腺癌
肿瘤微环境
发表日期：2020
文献求助 收藏

Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1)

致癌激酶NPM/ALK通过STAT3诱导免疫抑制蛋白CD274（PD-L1、B7-H1）的表达

期刊:Proceedings of the National Academy of Sciences of the United States of America
影响因子:9.1
doi:10.1073/pnas.0810958105
Marzec, Michal; Zhang, Qian; Goradia, Ami; Raghunath, Puthiyaveettil N; Liu, Xiaobin; Paessler, Michele; Wang, Hong Yi; Wysocka, Maria; Cheng, Mangeng; Ruggeri, Bruce A; Wasik, Mariusz A
肿瘤
肿瘤免疫
JAK/STAT
信号转导
ALK
PD-L1
CD274
STAT3
NPM
CD27
CD2
免疫/内分泌
发表日期：2008
文献求助 收藏